← All stocks

Axsome Therapeutics, Inc.

AXSM Mostly scheduled

CIK 0001579428 #896 in the set updated 17 Sep 2026

Bought (120 mo)

$1.56M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$194.52M

$23.44M on a plan · $170.75M straight out of an exercise

Sold at will

$322.47K

1 of 73 sales

Net

−$192.96M

+$1.24M against sales at will

By person

9 insiders · 117 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

TABUTEAU HERRIOT

Chief Executive Officer

—

$110.58M (20) scheduled

−$110.58M

7,229

0.0138%

$1.51M

0.0%

Jacobson Mark L.

Chief Operating Officer

—

$28.81M (13) scheduled

−$28.81M

0.0000%

$0.00

—

JEFFS ROGER

Director

$147.35K (1)

$15.77M (11) scheduled

−$15.63M

58,367

0.1114%

$12.18M

+1,234%

Pizzie Nick

Chief Financial Officer

$351.24K (11)

$12.13M (4) scheduled

−$11.78M

43,009

0.0821%

$8.97M

+5,435%

Coleman Mark

Director

$866.84K (11)

$12.33M (12) scheduled

−$11.46M

434,245

0.8290%

$90.61M

+9.1%

Saad Mark E

Director

$192.08K (5)

$8.35M (4) scheduled

−$8.16M

11,531

0.0220%

$2.41M

+249.2%

Murdock Hunter R.

General Counsel

—

$3.65M (5) scheduled

−$3.65M

0.0000%

$0.00

—

Maizel Ari

Chief Commercial Officer

—

$2.75M (2) scheduled

−$2.75M

0.0000%

$0.00

—

Mahony Susan

Director

—

$145.02K (2) scheduled

−$145.02K

829

0.0016%

$172.97K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Coleman Mark

20 May 2025

Director

Sell

3,000

$107.49

$322.47K

Show all 117 transactions →

What was left out

Form 4 filings counted 178

Amendments (4/A) skipped 2

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 19

Sales straight out of an exercise 53

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 2,185,486

History held since 17 Mar 2017